Share MacuSight is currently recruiting patients with wet AMD for a Phase 2 study of an ocular sirolimus formulation in combination with Lucentis®.  This is a randomized, multi-center study and is taking place throughout the United States.    

Participants with newly diagnosed wet AMD or patients with wet AMD that have been treated up to three times with Lucentis or Avastin may be eligible. Each patient will receive either one of three treatments: sirolimus at a lower dose in combination with Lucentis, sirolimus at a higher dose in combination with Lucentis or placebo in combination with Lucentis.

Eligibility criteria include being diagnosed with sub-foveal CNV secondary to wet AMD within six months of initial study visit or newly diagnosed patients and a visual acuity of 20/40 to 20/200 in the study eye.  For more information, please contact Celine Delpouys at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .